ReviewiScience2022
A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens.
Review in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Precision phage therapy in the AI/ML era: a systematic review of discovery-to-clinical translation evidence.Frontiers in microbiology · 2026Pooled it
- Cross-order detection of bacteriophage transduction in microbial communities using RNA barcoding.Nature communications · 2026Article
- Drug-Resistant Infections in Burn Patients: A One-Year Analysis of Microbiological Trends and Predictive Risk Factors in a Romanian Tertiary Care Centre.Antibiotics (Basel, Switzerland) · 2026Article
- Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Phage biobanks as enabling infrastructure for precision phage therapy in the era of antimicrobial resistance.Frontiers in antibiotics · 2026Article
- A phage cocktail with bactericidal and virulence-attenuating effects against dairy-associated hypervirulentCurrent research in food science · 2026Article
- Gene co-occurrence and its association with phage infectivity in bacterial pangenomes.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Review
- Completing the BASEL phage collection to unlock hidden diversity for systematic exploration of phage-host interactions.PLoS biology · 2025Article
- Molecular characterization and safety properties of multi drug-resistant Escherichia coli O157:H7 bacteriophages.BMC microbiology · 2024Article
- Designing a simple and efficient phage biocontainment system using the amber suppressor initiator tRNA.Archives of virology · 2024Article
- Bacteriophage therapy- a refurbished age-old potential strategy to treat antibiotic and multidrug resistant bacterial infections in future.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy.BMC microbiology · 2024Review
- The Citizen Phage Library: Rapid Isolation of Phages for the Treatment of Antibiotic Resistant Infections in the UK.Microorganisms · 2024Article
- Systematic and scalable genome-wide essentiality mapping to identify nonessential genes in phages.PLoS biology · 2023Article
- Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics.Molecular biology reports · 2023Review
- High-throughput approaches to understand and engineer bacteriophages.Trends in biochemical sciences · 2023Review
- Review
- A Perspective on Studies of Phage DNA Packaging Dynamics.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At its current rate, the rise of antimicrobial-resistant (AMR) infections is predicted to paralyze our industries and healthcare facilities while becoming the leading global cause of loss of human life. With limited new antibiotics on the horizon, we need to invest in alternative solutions. Bacteriophages (phages)-viruses targeting bacteria-offer a powerful alternative approach to tackle bacterial infections. Despite recent advances in using phages to treat recalcitrant AMR infections, the field lacks systematic development of phage therapies scalable to different applications. We propose a Phage Foundry framework to establish metrics for phage characterization and to fill the knowledge and technological gaps in phage therapeutics. Coordinated investment in AMR surveillance, sampling, characterization, and data sharing procedures will enable rational exploitation of phages for treatments. A fully realized Phage Foundry will enhance the sharing of knowledge, technology, and viral reagents in an equitable manner and will accelerate the biobased economy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.